Short Interest & Crowding

Short Interest & Crowding

Reported short interest in Zoetis stood at 14.80M shares (3.54% of float, $1.70B notional, 3.8 days to cover) at the April 30, 2026 NYSE settlement — roughly 2x the May 2025 level, and only modestly off the 17.30M / 4.1% peak set on February 27, 2026, a week after the company guided FY2026 to 3-5% organic growth. The May 7 guidance cut therefore landed into a tape that was already meaningfully — but not extremely — short, and the off-exchange short-sale volume ratio spiked to 45.5% on May 7 versus a 25-35% baseline. Despite the buildup, the borrow remains general-collateral (0.41% fee, ~7-8M shares freely available) and no credible short-seller report has been published, so this is variant-perception positioning rather than a borrow-constrained crowded short — short interest is decision-useful as a sentiment input and a thesis-validation signal, but it does not create squeeze, locate, or forced-cover risk.

Bottom Line for the PM

What the data says. Zoetis is not crowded by absolute standards (3.54% of float; days-to-cover under 4) but the level represents the highest sustained short positioning in the company's post-IPO history by a wide margin. The doubling from ~7M in 1H 2025 to ~15-17M by early 2026 happened before the May 7 guidance cut and the 21.5% decline — meaning shorts collectively read the underlying franchise risk (Librela dermatology competition, Fiscal Year Alignment pull-forward, slowing operational growth) ahead of the print rather than after. The post-print reaction was so violent in part because shorts who had built ahead of the event took profits and longs distributed simultaneously: technicals show 28.9M shares (~6.8x average) traded on May 7 with the FINRA off-exchange short-volume ratio at 45.5%, the highest weekly print of the year.

What it does not say. There is no public short-seller report (Muddy Waters / Hindenburg / Spruce Point / Kerrisdale style) on Zoetis. The plaintiff-firm "securities fraud investigations" announced May 13-18, 2026 are lawyer solicitations, not forensic short campaigns; they target the gap between February guidance and the May print, not allegations of accounting fraud. The borrow market is treating ZTS as general collateral (0.41% annualized fee, ample lendable supply), which is what you would expect for a $35B large-cap with diversified institutional ownership.

Reported Short Interest — 14-Month History

Short positioning roughly doubled between July 2025 (6.9M shares) and February 27, 2026 (17.3M peak) — the largest sustained build in Zoetis's post-IPO history. The trajectory tracks the franchise concerns building through late 2025: Librela US market-share losses to Elanco's Numelvi, the December 2025 BofA downgrade to Neutral, and the Q4 2025 print on February 11, 2026 where management telegraphed the Fiscal Year Alignment pull-forward. Shorts trimmed modestly between March and April (15.7M → 13.5M → 14.8M) but maintained position into the May 7 event, suggesting collective conviction that February guidance would not hold.

Float-adjusted, short interest sits at 3.54% — historically high for ZTS but moderate in absolute terms. By comparison, biopharma names like Pacira (21.2%), Omeros (25.1%), and Nektar (12.5%) are genuinely crowded; large-cap pharma like Bristol Myers (1.5%) is genuinely lightly shorted. ZTS now sits in a "watch but not crowded" zone — meaningful enough to count as a market view, not large enough to create forced-cover dynamics in a rally.

Source class: official reported short interest (NYSE-supplied position data). Twice-monthly cadence; latest available settlement is April 30, 2026.

Crowding vs Liquidity

Days-to-cover is the right lens — not raw float percentage — for assessing whether existing shorts can exit without moving the tape.

The crowding math is benign. Even using the slower 5-day ADV that produces the 3.8 day metric, every short would clear in under a week of normal volume; at the post-crash 20-day ADV of 8.5M shares, days-to-cover compresses to 1.74 days. Liquidity has actually expanded since May 7 because the distribution event roughly doubled average daily volume — mechanically reducing crowding pressure on anyone holding short. A 5% portfolio long is implementable in 5 days at 20% of ADV; symmetrically, the entire reported short position could be covered in roughly two normal trading sessions if shorts decided to capitulate together.

Source class: MarketBeat-aggregated reported short interest, healthcare sub-sector. The peer set is broad "medical" rather than animal-health pure-plays — Zoetis's direct competitors Elanco (ELAN) and IDEXX (IDXX) were not in the source's auto-comparison block.

ZTS sits in the low-to-mid third of healthcare names by float-percentage shorted. It is well above the 1-2% level typical of mega-cap pharma but well below the 10-25% zone where stocks routinely squeeze or face borrow constraints. The honest read: short interest is informative as a sentiment signal but not structurally decision-changing on its own.

Borrow Pressure — Easy to Borrow, No Locate Friction

The borrow fee held in a tight 0.41-0.42% band across the May 7 plunge and the entire two-week reaction window — that is general-collateral pricing, the floor of the rate scale. A borrow demand spike would push this to 1%+ within hours; a true hard-to-borrow situation reads at 10%+. There is no evidence of locate friction in the data window: 7-8 million shares were consistently available to short at a single prime broker (a partial-sample indicator, not aggregate market supply).

Source class: single-prime-broker availability snapshot (public indicator); not market-wide lendable supply and not a substitute for aggregate borrow-utilization data, which is not available in this snapshot.

Implication for the long thesis. If you want to be long ZTS, you cannot lean on a squeeze tailwind — there is no fuel. Conversely, if you are short, you do not need to worry about a forced-cover event from borrow-recall mechanics; the position can be sustained at de-minimis carry cost.

Tape Around the May 7 Event — Short-Sale Volume Spike

What this is and what it is not. This is daily trading-flow short volume (off-exchange, FINRA-reported, includes dark-pool short prints). It is not outstanding short interest and should never be summed into a "position." A 45.5% short-volume ratio on May 7 means that of every 100 shares that traded in dark pools that day, 45-46 were marked as short sales; the remainder were either long sales or buys. The number captures the speed at which the tape was being shorted into intraday, not the total size of the bet.

Reading the tape. The 45.5% reading on May 7 is unambiguously elevated versus the 25-35% baseline that prevailed in the following two weeks. Combined with the technicals-claude finding of 6.8x average volume and a -21.5% close on institutional distribution, the picture is one of long holders dumping into a market that was simultaneously being aggressively shorted intraday. The May 19 re-elevation (47.3%) at lower total volume is noise (denominator effect); the May 7 print is the signal.

For thesis interpretation: the reported-short-interest series (above) tells you that the bearish position was built ahead of the event. The short-sale-volume series tells you that more shorts were added into the print on the day. A meaningful chunk of those intraday additions likely covered by month-end, which is why reported short interest at 4/30 (14.8M) sits below the 2/27 peak (17.3M) — but it remains elevated.

Short-Thesis Evidence Ledger — What is Actually Out There

The thesis ledger reads as consensus bearish, not adversarial. What is striking is what is missing: no Muddy-Waters-style accounting report, no Hindenburg-style fraud allegation, no Spruce-Point-style governance attack. The bear case is in the open — Librela demand decay, Fiscal Year Alignment optics, slowing operational growth, post-2030 patent cliff for Apoquel and Simparica Trio — and is reflected in sell-side downgrades and the position build. Plaintiff-firm investigations are reaction to the price move, not a cause of it.

Evidence Quality & Limitations

Key limitations to flag for the PM.

The pre-staged FINRA short-interest dataset for ZTS came back empty in this run; the position-level numbers used above were sourced from third-party aggregators (Fintel, MarketBeat, Finviz) that re-publish the NYSE-supplied official short interest on a twice-monthly cadence. The 14.80M / 3.54% / 3.8 DTC figures are official position data — the only gap is that the data path was supplier-aggregator rather than FINRA-direct.

No aggregate borrow utilization (the Ortex/S3 institutional metric that tells you what fraction of lendable supply is actually borrowed) is available in this snapshot. The 0.41% fee and 7-8M shares-available numbers come from a single prime-broker public indicator; they suggest no scarcity, but the negative case — that borrow could spike sharply if any of the larger lenders pulled supply — cannot be ruled out from this evidence base alone.

No direct animal-health peer comparison. The aggregator returned generic healthcare peers; the appropriate peer set for crowding judgment is Elanco (ELAN) and IDEXX (IDXX) — neither was in the auto-comparison block. ZTS short interest at 3.54% is "moderate" in the broad pharma sense but its standing versus direct vet-pharma peers is not established here.

Market Setup — How This Changes the Investment Case

For a long thesis. The 14.8M short position is a sentiment headwind, not a structural problem. There is no squeeze fuel: borrow is general collateral, days-to-cover under 4, and shorts can exit in any rally without coordination. The constructive read is that part of the 21.5% May 7 reset was short-driven distribution and the structural overhang is therefore smaller than the price action implied. The cautious read is that 3.54% short interest is the highest in the company's post-IPO life and shorts collectively anticipated the franchise concerns — that variant perception is now public, but it is not capitulating.

For a short thesis. The position is defensible to maintain but expensive to add aggressively here. At 0.41% borrow and post-crash valuation (13x P/E vs ~30x historical average), the risk-reward of a fresh short on incremental size is less attractive than the original entry at $150+; sell-side average target at $149 implies the consensus does not yet see further downside, which creates re-rating risk on any Q2 stabilization print. The forensic yellow flags (DSO build, FYA pull-forward) keep the thesis alive but require a Q2 catalyst to compound.

For catalyst interpretation. Position into mid-August Q2 print: shorts likely trim into any working-capital normalization (DSO back below 52 days, distributor inventory normalization), creating short-cover bid into a clean print. Conversely, a second guidance reset or another International miss would likely trigger fresh shorts adding into the move, with locate still easily available. No options-driven gamma squeeze setup exists — implied volatility was 29% pre-event and put pricing has continued downside through Jan 2028.

For sizing and risk controls. The short-interest data does not justify reducing position size on its own; it does justify (a) tracking the next two NYSE settlement reports (5/15 and 5/29 2026) to see whether the May 7 event caused profit-taking and a drop back toward 10M shares, or whether shorts have re-added through the unwind, and (b) monitoring whether the borrow fee breaches 1% — that would be the first hard signal that aggregate borrow demand is exceeding lendable supply and the dynamics are changing.